Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093942000> ?p ?o ?g. }
- W3093942000 endingPage "996" @default.
- W3093942000 startingPage "996" @default.
- W3093942000 abstract "Ephrin receptor A2 (EphA2) is a member of the Ephrin/Eph receptor cell-to-cell signaling family of molecules, and it plays a key role in cell proliferation, differentiation, and migration. EphA2 is overexpressed in a broad range of cancers, and its expression is in many cases associated with poor prognosis. We recently developed a novel EphA2-targeting antibody-directed nanotherapeutic encapsulating a labile prodrug of docetaxel (EphA2-ILs-DTXp) for the treatment of EphA2-expressing malignancies. Here, we characterized the expression of EphA2 in bladder cancer using immunohistochemistry in 177 human bladder cancer samples and determined the preclinical efficacy of EphA2-ILs-DTXp in four EphA2-positive patient-derived xenograft (PDX) models of the disease, either as a monotherapy, or in combination with gemcitabine. EphA2 expression was detected in 80–100% of bladder cancer samples and correlated with shorter patient survival. EphA2 was found to be expressed in tumor cells and/or tumor-associated blood vessels in both primary and metastatic lesions with a concordance rate of approximately 90%. The EphA2-targeted antibody-directed nanotherapeutic EphA2-ILs-DTXp controlled tumor growth, mediated greater regression, and was more active than free docetaxel at equitoxic dosing in all four EphA2-positive bladder cancer PDX models. Combination of EphA2-ILs-DTXp and gemcitabine in one PDX model led to improved tumor growth control compared to monotherapies or the combination of free docetaxel and gemcitabine. These data demonstrating the prevalence of EphA2 in bladder cancers and efficacy of EphA2-ILs-DTXp in PDX models support the clinical exploration of EphA2 targeting in bladder cancer." @default.
- W3093942000 created "2020-10-29" @default.
- W3093942000 creator A5007255501 @default.
- W3093942000 creator A5008160506 @default.
- W3093942000 creator A5008947426 @default.
- W3093942000 creator A5015750329 @default.
- W3093942000 creator A5020173185 @default.
- W3093942000 creator A5020903534 @default.
- W3093942000 creator A5027344464 @default.
- W3093942000 creator A5038349275 @default.
- W3093942000 creator A5038520217 @default.
- W3093942000 creator A5040346750 @default.
- W3093942000 creator A5046151634 @default.
- W3093942000 creator A5054359239 @default.
- W3093942000 creator A5059394561 @default.
- W3093942000 creator A5063400337 @default.
- W3093942000 creator A5064961562 @default.
- W3093942000 creator A5066009774 @default.
- W3093942000 creator A5066534101 @default.
- W3093942000 creator A5072389805 @default.
- W3093942000 creator A5074272646 @default.
- W3093942000 date "2020-10-20" @default.
- W3093942000 modified "2023-10-18" @default.
- W3093942000 title "Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic" @default.
- W3093942000 cites W1525764794 @default.
- W3093942000 cites W1964166386 @default.
- W3093942000 cites W1966023125 @default.
- W3093942000 cites W1966339980 @default.
- W3093942000 cites W1966672503 @default.
- W3093942000 cites W1986708715 @default.
- W3093942000 cites W1997670728 @default.
- W3093942000 cites W2000000810 @default.
- W3093942000 cites W2010352423 @default.
- W3093942000 cites W2029838406 @default.
- W3093942000 cites W2034073392 @default.
- W3093942000 cites W2036519126 @default.
- W3093942000 cites W2049553585 @default.
- W3093942000 cites W2068523052 @default.
- W3093942000 cites W2074480887 @default.
- W3093942000 cites W2082338146 @default.
- W3093942000 cites W2094663537 @default.
- W3093942000 cites W2103257412 @default.
- W3093942000 cites W2109850440 @default.
- W3093942000 cites W2115472066 @default.
- W3093942000 cites W2127556545 @default.
- W3093942000 cites W2129909745 @default.
- W3093942000 cites W2129927968 @default.
- W3093942000 cites W2131884474 @default.
- W3093942000 cites W2134514535 @default.
- W3093942000 cites W2134642258 @default.
- W3093942000 cites W2148562299 @default.
- W3093942000 cites W2154029052 @default.
- W3093942000 cites W2406161911 @default.
- W3093942000 cites W2546935275 @default.
- W3093942000 cites W2554756905 @default.
- W3093942000 cites W2559804019 @default.
- W3093942000 cites W2560367415 @default.
- W3093942000 cites W2588916311 @default.
- W3093942000 cites W2760661635 @default.
- W3093942000 cites W2777192533 @default.
- W3093942000 cites W2779221466 @default.
- W3093942000 cites W2781525129 @default.
- W3093942000 cites W2784644201 @default.
- W3093942000 cites W2884890286 @default.
- W3093942000 cites W2910573029 @default.
- W3093942000 cites W2928361908 @default.
- W3093942000 cites W2980259851 @default.
- W3093942000 cites W3010197652 @default.
- W3093942000 cites W3023288864 @default.
- W3093942000 cites W4242669880 @default.
- W3093942000 doi "https://doi.org/10.3390/pharmaceutics12100996" @default.
- W3093942000 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7589819" @default.
- W3093942000 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33092175" @default.
- W3093942000 hasPublicationYear "2020" @default.
- W3093942000 type Work @default.
- W3093942000 sameAs 3093942000 @default.
- W3093942000 citedByCount "6" @default.
- W3093942000 countsByYear W30939420002022 @default.
- W3093942000 countsByYear W30939420002023 @default.
- W3093942000 crossrefType "journal-article" @default.
- W3093942000 hasAuthorship W3093942000A5007255501 @default.
- W3093942000 hasAuthorship W3093942000A5008160506 @default.
- W3093942000 hasAuthorship W3093942000A5008947426 @default.
- W3093942000 hasAuthorship W3093942000A5015750329 @default.
- W3093942000 hasAuthorship W3093942000A5020173185 @default.
- W3093942000 hasAuthorship W3093942000A5020903534 @default.
- W3093942000 hasAuthorship W3093942000A5027344464 @default.
- W3093942000 hasAuthorship W3093942000A5038349275 @default.
- W3093942000 hasAuthorship W3093942000A5038520217 @default.
- W3093942000 hasAuthorship W3093942000A5040346750 @default.
- W3093942000 hasAuthorship W3093942000A5046151634 @default.
- W3093942000 hasAuthorship W3093942000A5054359239 @default.
- W3093942000 hasAuthorship W3093942000A5059394561 @default.
- W3093942000 hasAuthorship W3093942000A5063400337 @default.
- W3093942000 hasAuthorship W3093942000A5064961562 @default.
- W3093942000 hasAuthorship W3093942000A5066009774 @default.
- W3093942000 hasAuthorship W3093942000A5066534101 @default.
- W3093942000 hasAuthorship W3093942000A5072389805 @default.